Iterum Therapeutics (NASDAQ:ITRM) Stock Price Down 2% – Should You Sell?

by · The Cerbat Gem

Iterum Therapeutics PLC (NASDAQ:ITRM – Get Free Report) traded down 2% during trading on Monday . The stock traded as low as $0.4334 and last traded at $0.4510. 878,262 shares were traded during mid-day trading, a decline of 27% from the average session volume of 1,198,617 shares. The stock had previously closed at $0.46.

Analyst Ratings Changes

A number of research firms recently commented on ITRM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iterum Therapeutics in a report on Monday. Wall Street Zen cut shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.00.

Get Our Latest Report on Iterum Therapeutics

Iterum Therapeutics Price Performance

The company has a 50-day moving average of $0.61 and a 200 day moving average of $0.77. The company has a market cap of $22.02 million, a PE ratio of -0.56 and a beta of 2.91.

Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The firm had revenue of $0.39 million during the quarter. Equities research analysts expect that Iterum Therapeutics PLC will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Iterum Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Iterum Therapeutics in the third quarter worth about $32,000. Jane Street Group LLC purchased a new position in Iterum Therapeutics during the 2nd quarter valued at $92,000. Finally, OneDigital Investment Advisors LLC grew its position in Iterum Therapeutics by 18.6% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after acquiring an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Stories